Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.00%
)
US TECH 100
28,321.13
(
-1.63%
)
Dow Jones
50,063.46
(
0.00%
)
Brent Oil
105.71
(
1.46%
)
Bitcoin
80,420.01
(
-0.79%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 218584

Wednesday, 04/18/2018 7:21:22 PM

Wednesday, April 18, 2018 7:21:22 PM

Post# of 257566
ASMB—The phase-2a trial design is ok, but I don't buy the stated reason for restricting the trial to e-antigen+ patients.

What is the real reason for the exclusion? Maybe that they don't yet know what dose to use in e-antigen- patients, based on the flattish dose-response curve in phase-1.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today